Journal
CURRENT ONCOLOGY REPORTS
Volume 24, Issue 10, Pages 1299-1311Publisher
SPRINGER
DOI: 10.1007/s11912-022-01286-0
Keywords
Bruton's tyrosine kinase; Chimeric antigen receptor T-cell therapy; Relapsed; refractory mantle cell lymphoma; Combination therapy
Categories
Funding
- BeiGene, Inc.
Ask authors/readers for more resources
This review focuses on the feasibility of combining Bruton's tyrosine kinase inhibitors with chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma patients. The authors present potential scenarios for the combination treatment and suggest that it may improve CAR T-cell efficacy.
Purpose of Review This review focuses on the feasibility of combining Bruton's tyrosine kinase (BTK) inhibitors (BTKis) with chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Potential scenarios for combination treatment with these agents are presented. Recent Findings BTKis and CAR T-cell therapy have revolutionized the treatment paradigm for R/R MCL. Ibrutinib, acalabrutinib, and zanubrutinib are covalent irreversible BTKis approved for R/R MCL. Brexucabtagene autoleucel was the first CAR T-cell therapy approved for R/R MCL based on findings from the ZUMA-2 trial. There is evidence to suggest that combination treatment with BTKis and CAR T-cell therapy may improve CAR T-cell efficacy. As BTKis and CAR T-cell therapy become mainstays in R/R MCL therapy, combination treatment strategies should be evaluated for their potential benefit in R/R MCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available